EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Enhanced melanoma-specific cytotoxic T-cell expansion and the clinical outcomes with simlukafusp alfa and pembrolizumab following checkpoint inhibitor progression

Fabian Junker, Martine Darwish, Mahesh Yadav, Christin Habigt, Tobias Bergauer, David Dejardin, José Duarte, Eva Muñoz-Couselo, Oliver Bechter, Volker Teichgräber, Nino Keshelava, Anton Kraxner und 1 weitere

Journal for ImmunoTherapy of Cancer · 2026-11 · 14 (11) · e015065

DOI: 10.1136/jitc-2026-015065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 02.11.2026. Verfasst von Fabian Junker und 12 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: F. Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite advances in checkpoint inhibitor (CPI) therapy, a substantial proportion of patients with advanced melanoma experience disease progression, and the capacity of CD8 + cytotoxic T lymphocytes (CTLs) specific for wild-type melanoma-associated antigens to persist and remain functionally inducible after CPI failure is poorly understood. Here we report exploratory translational analyses from the BP41054 Phase I trial investigating the combination of simlukafusp alfa (FAP-IL2v), a tumor stroma-targeted IL-2 variant, with pembrolizumab in CPI-experienced patients with advanced melanoma.MethodsPeripheral blood mononuclear cells from a subset of 33 CPI-experienced patients were profiled at baseline (C1D1_pre) and on treatment (C2D8) using quantitative immunophenotyping and a panel of 28 melanoma-associated peptide–HLA tetramers spanning 14 antigens and multiple HLA alleles. Antigen-specific CTLs were further characterized functionally by ex vivo peptide challenge and interferon (IFN)-γ intracellular staining. Associations with progression-free survival (PFS) were assessed as exploratory endpoints.

Results

Treatment was associated with increased circulating natural killer cells and CD8 + T cells, including effector memory and terminally differentiated effector subsets, as assessed in peripheral blood. CTLs specific for 11 unique peptide-major histocompatibility complexes were identified, with increased frequencies detected during treatment in a subset of patients. These antigen-specific CTLs demonstrated functional activity as indicated by IFN-γ production on peptide challenge, though responses were variable across peptide specificities and patients, and direct cytotoxic activity was not assessed. Signs of incomplete functional rescue, including persistent co-expression of exhaustion markers, were observed. In exploratory descriptive analyses, patients whose antigen-specific CTL diversity increased on treatment had a longer median PFS than those in whom diversity was reduced; with three patients per group, these outcomes are reported descriptively, without formal statistical comparison. Baseline melanoma-associated immunity did not predict clinical outcome.

Conclusions

These hypothesis-generating findings indicate that melanoma-specific CD8 + T-cell immunity persists and remains inducible in CPI-experienced patients, supporting the rationale for strategies that re-engage residual antitumor immunity. Validation in larger cohorts with paired tumor and blood sampling will be required to establish clinical relevance.

Schlagwörter

Stichwörter der Autor:innen

CytokineImmune Checkpoint InhibitorImmunotherapyMelanomaTumor Microenvironment

Autor:innen und Institutionen

  • Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Roche Holdings Inc, South San Francisco, California, USA.
  • Oncology Biomarker Development, Genentech Inc, South San Francisco, California, USA.
  • Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Department of Biostatistics, F Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.

Förderung

  • F. Hoffmann-La Roche

Zitieren

APA

Junker, F., Darwish, M., Yadav, M., Habigt, C., Bergauer, T., Dejardin, D., Duarte, J., Muñoz-Couselo, E., Bechter, O., Teichgräber, V., Keshelava, N., Kraxner, A., & Charo, J. (2026). Enhanced melanoma-specific cytotoxic T-cell expansion and the clinical outcomes with simlukafusp alfa and pembrolizumab following checkpoint inhibitor progression. Journal for ImmunoTherapy of Cancer, 14(11), e015065. https://doi.org/10.1136/jitc-2026-015065

Vancouver

Junker F, Darwish M, Yadav M, Habigt C, Bergauer T, Dejardin D, et al. Enhanced melanoma-specific cytotoxic T-cell expansion and the clinical outcomes with simlukafusp alfa and pembrolizumab following checkpoint inhibitor progression. Journal for ImmunoTherapy of Cancer. 2026;14(11):e015065. doi:10.1136/jitc-2026-015065

BibTeX
@article{Junker2026,
  author = {Junker, Fabian and Darwish, Martine and Yadav, Mahesh and Habigt, Christin and Bergauer, Tobias and Dejardin, David and Duarte, José and Muñoz-Couselo, Eva and Bechter, Oliver and Teichgräber, Volker and Keshelava, Nino and Kraxner, Anton and Charo, Jehad},
  title = {Enhanced melanoma-specific cytotoxic T-cell expansion and the clinical outcomes with simlukafusp alfa and pembrolizumab following checkpoint inhibitor progression},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {11},
  pages = {e015065},
  doi = {10.1136/jitc-2026-015065}
}
Kostenlos starten →